Loading data for IBRX — first visit, this takes a few seconds.
ImmunityBio Inc. (IBRX)
: IBRX
· Echtzeitkurs · USD
n/a
n/a (n/a)
Zum Schluss: Invalid Date
ImmunityBio Inc. (IBRX) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | n/a |
| Umsatz (TTM) | 165.79 Mio |
| Nettogewinn (TTM) | -992.36 Mio |
| Beta | 0.12 |
| EPS (ttm) | n/a |
| KGV (TTM) | n/a |
| Forward-KGV | -60.95 |
| KBV (TTM) | -7.77 |
| KUV (TTM) | 49.35 |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | NaN |
| Ø Vol. (20D) | n/a |
| Eröffnung | n/a |
| Vortagesschluss | n/a |
| Tagesspanne | n/a - n/a |
| 52-Wk Range | n/a - n/a |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated ...
Branche Biotechnology
Sektor Healthcare
IPO Datum Jul 28, 2015
Mitarbeiter 684
Börse NasdaqGS
Tickersymbol IBRX
Website https://immunitybio.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von ImmunityBio 113.29 Mio, ein Anstieg von 668.31% im Vergleich zum Vorjahr (14.74 Mio). Der Gewinn lag bei -351.4 Mio, ein Rückgang von -15.03 %.
Finanzberichte